At one year after transplant, kidney allograft function, rejection rates similar regardless of donor hepatitis C status<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Dec. 18, 2020 (HealthDay News) — Recipients of kidneys from donors infected with hepatitis C virus (HCV) have similar kidney allograft function and probability of rejection in the first year after transplantation as those who receive kidneys from donors without HCV infection, according to a study published online Dec. 14 in the American Journal of Kidney Diseases<\/em>.<\/p>\n Miklos Z. Molnar, M.D., Ph.D., from the University of Tennessee Health Science Center in Memphis, and colleagues retrospectively reviewed kidney allograft function and allograft biopsy findings for 65 HCV-negative recipients who received a kidney from an HCV-infected donor (HCV+) and 59 HCV-negative recipients who received a kidney from a donor without HCV infection (HCV\u00e2\u0088\u0092) during 2018 at a single transplant center.<\/p>\n The researchers observed no differences between the HCV+ and HCV\u00e2\u0088\u0092 groups with respect to delayed graft function rates (12 versus 8 percent); estimated glomerular filtration rate (eGFR) posttransplant at three, six, nine, and 12 months; proportion of patients with cellular rejection (6 versus 7 percent); and proportion with antibody-mediated rejection (7 versus 10 percent) or de novo donor-specific antibodies (31 versus 20 percent). There was no association between HCV viremic status and eGFR at three, six, nine, or 12 months.<\/p>\n “Transplantation of kidneys from HCV-infected donors to HCV-negative recipients leads to excellent one-year posttransplant outcomes,” the authors write.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n